港股异动 | 歌礼制药-B(01672)现涨超6% 药企积极布局超长效新疗法 公司已有ULAP技术平台

智通财经
Nov 25, 2025

智通财经APP获悉,歌礼制药-B(01672)现涨超6%,截至发稿,涨6.25%,报14.46港元,成交额3959.18万港元。

消息面上,11月13日,辉瑞宣布已成功完成对Metsera公司的收购,交易总价值约92亿美元;通过本次收购,辉瑞将获得Metsera核心资产MET-097i与MET-233i。礼来诺和诺德也积极布局超长效平台,2025年已分别与Camurus与Ascendis完成战略合作,将利用它们的FluidCrystal与TransCon皮下储库缓控释技术开发超长效减重降糖类产品。

开源证券发布研报称,随着未来越来越多临床数据的披露,超长效管线与技术平台的价值将逐步凸显,我们预计超长效新疗法将成为减重降糖赛道最有差异化的竞争方向。该行指出,抗体偶联、脂肪酸端基修饰、皮下储库缓控释等多项技术能实现超长效给药,其中,歌礼制药已布局皮下储库ULAP技术平台,利用该平台已开发了多款超长效减肥药管线。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10